News

In December last year, Evaxion secured the FDA approval to advance with its Phase IIb clinical trial, where EVX-01 is given along with KEYTRUDA to patients with metastatic

The recombinant adeno-associated virus (rAAV)-based gene therapy is being studied to treat neovascular Age Related Macular Degeneration (nAMD), which causes severe loss of vision and irreversible blindness across

The adeno-associated viral serotype rh10 (AAVrh10) gene therapy FBX-101 is delivered intravenously after hematopoetic stem cell transplant (HSCT) infusion. The designation for this lead adeno-associated virus (AAV) drug

The tocilizumab injection, BAT1806 is a recombinant humanised monoclonal antibody which has been developed to target interleukin-6 receptor (IL-6R). IL-6R specially binds to soluble and membrane-bound IL-6 receptors

Lecanemab is intended for the treatment of mild cognitive impairment (MCI) due to AD and mild AD dementia with confirmed amyloid pathology presence in the brain. The application

DS-5670 is an mRNA vaccine being developed against the novel coronavirus infectious disease (COVID-19). It is proposed to be used as a booster vaccine to prevent Covid-19. The

Myelin is an insulating material that allows proper function of neurons. It made of specialised cells of the nervous system called oligodendrocytes. This myelin sheath offers a protective

The inhaled mRNA-based therapeutic is intended for people with CF, including those with genotypes that are not responsive to approved CFTR modulators. ReCode Therapeutics CEO Shehnaaz Suliman said:

The FDA is expected to complete the NDA review in October this year and stated that it currently has no plans to hold an advisory committee meeting to